ERBB2 and cancer: A HER2‐targeting ADC comprising a cancer‐selective cleavable β‐glucuronide linker, an anti‐HER2 antibody derived from trastuzumab, and an antimitotic agent, monomethyl auristatin F (MMAF), which inhibits tubulin polymerization